Abbott Molecular has launched its CE-Marked Abbott HBV Sequencing test in the European Union. The test is the first sequencing-based diagnostic to be developed by Abbott, and was developed on Life Technologies' CE 3130 DNA sequencing system.
According to the company, the test identifies the DNA sequence of the hepatitis B virus polymerase gene, including all clinically relevant HBV drug resistant mutations.
This molecular diagnostic test was developed to help physicians monitor HBV infections, guide treatment decisions, and predict or discover drug resistance. It is not intended for screening blood donors, plasma, or tissue donors for HBV, or to be used as a diagnostic test to confirm the presence of HBV infection, Abbott said.